New PET tracer could light up brain tumors
NCT ID NCT03465618
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 study tests a new PET imaging tracer called 89Zr-cRGDY in 17 people with malignant brain tumors or pituitary adenomas. The tracer is given in a very small dose to see how it spreads and clears from the body. The goal is to improve brain tumor imaging, not to treat the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-DFO-cRGDY-PEG-Cy5-C' dots (ultrasmall silica particle tracer)
What this could lead to
If successful, this imaging method could help doctors see brain tumors more clearly, potentially guiding future treatments.
What could go wrong
This is a very early, small study (17 people) testing a new tracer for the first time in humans. It is not designed to treat or cure cancer, and the tracer may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITUITARY ADENOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States